NEORX CORPORATION

Basic Information

410 W HARRISON ST
SEATTLE, WA, 98119

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. GEMCITABINE POTENTIATION OF PRETARGET RIT

    Amount: $108,679.00

    DESCRIPTION: Each year in the United States there are more than 20,000 deaths from pancreatic cancer. Gemcitabine is a cytarabine analogue that has been shown to be effective in prolo ...

    SBIR Phase I 2001 Department of Health and Human Services
  2. N/A

    Amount: $104,167.00

    N/A

    SBIR Phase II 2000 Department of Health and Human Services
  3. N/A

    Amount: $100,000.00

    N/A

    STTR Phase I 2000 Department of Health and Human Services
  4. N/A

    Amount: $0.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services
  5. ALPHA RADIOTHERAPY VIA PRETARGETED LEAD 212

    Amount: $753,164.00

    N/A

    SBIR Phase II 1998 Department of Health and Human Services
  6. COLD STORAGE OF PLATELETS

    Amount: $95,839.00

    N/A

    SBIR Phase I 1997 Department of Health and Human Services
  7. ALPHA RADIOTHERAPY VIA PRETARGETED LEAD 212

    Amount: $100,000.00

    N/A

    SBIR Phase I 1997 Department of Health and Human Services
  8. CONJUGATION OF SMALL RIBOSOMAL INHIBITORS TO ANTIBODIES

    Amount: $50,000.00

    NEORX CORPORATION PROPOSES A NEW SERIES OF SMALL-MOLECULAR WEIGHT NATURAL PRODUCTS THAT ARE SIMILAR TO HIGHER PLANT TOXINS IN THEIR MECHANISMS OF ACTION-INHIBITING PROTEIN SYNTHESIS AT THE LEVEL OF TH ...

    SBIR Phase I 1987 Department of Health and Human Services
  9. RADIOIODINATED CONJUGATES FOR THERAPY AND DIAGNOSIS

    Amount: $500,000.00

    THE PURPOSE OF THIS CONTRACT PROPOSAL IS TO DEVELOP NEW RADIOIODINE-LABELED CONJUGATES FOR MONOCLONAL ANTIBODIES THAT CAN BE USED IN DIAGNOSIS AND THERAPY OF CANCER. THE GOAL OF OUR PROPOSED RESEARCH ...

    SBIR Phase II 1986 Department of Health and Human Services
  10. RADIORHENIUM ANTIBODIES FOR RADIOIMMUNOTHERAPY

    Amount: $500,000.00

    THE OBJECTIVE OF THIS PHASE I SBIR PROJECT IS TO DEVELOP A RE-186 AGENT SUITABLE FOR LABELING BIFUNCTIONAL CHELATING AGENT ANTIBODY CONJUGATES. ALTHOUGH CHEMICALLY SIMILAR TO TC-99M, APPLICATION OF RE ...

    SBIR Phase II 1986 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government